Investing

Group Eleven Resources Corp. (TSXV: ZNG) (OTC Pink: GRLVF) is pleased to announce its participation at the upcoming New Orleans Investment Conference on Saturday, November 23rd at the Hilton New Orleans Riverside. Bart Jaworski, CEO of Group Eleven Resources Corp.

Gunnison Copper (TSX:GCU,OTCQB:EXMGF) is shifting its development strategy for the Gunnison copper project in Arizona, US, laying out plans for a conventional open-pit and heap-leach operation. In a preliminary economic assessment (PEA), released on Thursday (November 14), the company explains that

Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce progress on its ISLA-101 Phase 2a/b clinical trial in dengue fever. All key data samples have been collected following dosing of all

Lightning Minerals (L1M or the Company) is delighted to announce the discovery of spodumene within a lithium bearing pegmatite at the Company’s recently acquired Esperança project. The discovery supports the Company’s approach to exploration in the district and its positive

Provaris Energy Ltd (ASX.PV1, Provaris, the Company) is pleased to present the notice of initial substantial holder. Click here for the full ASX Release This post appeared first on investingnews.com

Description During a fireside chat with analysts from Brookline Capital Markets, Radiopharm Theranostics’ (ASX:RAD) CEO Riccardo Canevari provided clinical and corporate updates highlighting the company’s achievements while waiting for the completion of its listing on the NASDAQ expected at the end

Perth, Australia (ABN Newswire) – BPH Energy Limited (ASX:BPH) provide a presentation by investee Cortical Dynamics at the Health Innovation Frontier Forum on 18th November 2024. This event will showcase the intersection between technology, health and community. *To

Ionic Rare Earths Limited (“IonicRE” or the “Company”) (ASX: IXR) wholly owned subsidiary Ionic Technologies is on track for the development of a unique commercial REO manufacturing facility in Belfast, UK, following the successful completion of a Feasibility Study that

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that a clinical study featuring 68Ga-Trivehexin (68Ga-RAD 301), conducted by Dr. Rehm

Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) (‘Alvopetro’ or the ‘Company’) announces the annual rolling grants of long-term incentive compensation to officers, directors and employees under Alvopetro’s Omnibus Incentive Plan. A total of 251,000 stock options, 213,000 restricted share units